[
  {
    "text": "Thanksgivings.  We're talking today about rational   medicine, and really what we're talking about is an understanding of  ",
    "start": "0",
    "end": "10000"
  },
  {
    "text": "the molecular biology of disease has actually helped to revolutionize the  ",
    "start": "10000",
    "end": "16000"
  },
  {
    "text": "new science of therapeutic medicine.  And here, more often than not, the   discussions are focused around cancer.  And so,   ",
    "start": "16000",
    "end": "27000"
  },
  {
    "text": "I will therefore talk about an interesting story,    vis-Ã -vis the modern treatment of cancer, and how our understanding of  ",
    "start": "27000",
    "end": "37000"
  },
  {
    "text": "the molecular biology of the disease really helps in developing radically  ",
    "start": "37000",
    "end": "43000"
  },
  {
    "text": "new kinds of therapies.  By way of background,    let's just mention that most of the chemotherapeutics that we use today  ",
    "start": "43000",
    "end": "53000"
  },
  {
    "text": "to treat cancer were developed over the last 40-50 years at a time when   the molecular and biochemical defects inside cancer cells  ",
    "start": "53000",
    "end": "63000"
  },
  {
    "text": "were totally obscure.  And therefore,    to the extent that one developed chemotherapeutics,   ",
    "start": "63000",
    "end": "71000"
  },
  {
    "text": "they were developed simply empirically, trial and error.    For example, some of the most effective chemotherapeutics against  ",
    "start": "71000",
    "end": "78000"
  },
  {
    "text": "childhood leukemia are alkylating agents,      which attach methyl and ethyl groups  ",
    "start": "78000",
    "end": "90000"
  },
  {
    "text": "to target molecules inside cells.  And their utility in cancer was   first discerned because of an explosion in a container.   ",
    "start": "90000",
    "end": "101000"
  },
  {
    "text": "I think it was in a ship off Naples in World War II where a bin of   alkylating agents was dispersed.  Many people were exposed to it, and  ",
    "start": "101000",
    "end": "111000"
  },
  {
    "text": "these people, as a consequence of that, came down with what's  ",
    "start": "111000",
    "end": "117000"
  },
  {
    "text": "called leucopoenia.  Poenia generally means a depression,    in this case, a depression of their white blood cells.   ",
    "start": "117000",
    "end": "127000"
  },
  {
    "text": "Such alkylating agents had actually been used during the First World War   in gas warfare because during the First World War,   ",
    "start": "127000",
    "end": "137000"
  },
  {
    "text": "one used so-called mustard gases,  which was a very effective way, even   more effective than artillery in killing vast numbers  ",
    "start": "137000",
    "end": "147000"
  },
  {
    "text": "of enemy soldiers.  And, somebody noticed this   leucopoenia in 1946-47 as a consequence of inadvertent exposure  ",
    "start": "147000",
    "end": "156000"
  },
  {
    "text": "to these alkylating agents,  which became dispersed as a gas.    And about five years later,  somebody made the logical leap that  ",
    "start": "156000",
    "end": "165000"
  },
  {
    "text": "if these agents were able to suppress normal white blood   concentrations that perhaps they might also be effective against what  ",
    "start": "165000",
    "end": "174000"
  },
  {
    "text": "seemed to be ostensibly a related problem, which is the problem   of leukemia.  And keep in mind that when we talk  ",
    "start": "174000",
    "end": "183000"
  },
  {
    "text": "about leukemia,  the suffix -emia refers to blood   generally, and leuk- once again refers to white blood,   ",
    "start": "183000",
    "end": "193000"
  },
  {
    "text": "i.e. an excess of white blood cells in the blood.  And so,    through this accidental discovery,  one began to develop alkylating  ",
    "start": "193000",
    "end": "202000"
  },
  {
    "text": "agents that turned out to be extremely successful in treating,    and often curing, childhood leukemias, most notably acute  ",
    "start": "202000",
    "end": "212000"
  },
  {
    "text": "lymphocytic leukemia,  which turns out to be very sensitive   to this and other related agents.  So, this is a very common form of  ",
    "start": "212000",
    "end": "222000"
  },
  {
    "text": "childhood leukemia,  which is now actually cured in 60 or   70% of the children who were treated,  which would have been unheard of  ",
    "start": "222000",
    "end": "230000"
  },
  {
    "text": "half a century ago.  But I return to what I said before,    which is that this kind of treatment was developed in the face of total  ",
    "start": "230000",
    "end": "239000"
  },
  {
    "text": "ignorance concerning the nature of the disease, the molecular defects   that were present in the disease,  and that were responsible for the  ",
    "start": "239000",
    "end": "248000"
  },
  {
    "text": "runaway, can you still hear me OK,  were responsible for the runaway   proliferation of the cancer cells.  So having said that,   ",
    "start": "248000",
    "end": "257000"
  },
  {
    "text": "I want to go to a different kind of leukemia, and this is called chronic   myelogenous leukemia,  to give you an indication of the  ",
    "start": "257000",
    "end": "268000"
  },
  {
    "text": "path of discovery that led from its original description to the   development of rather successful treatments.   ",
    "start": "268000",
    "end": "279000"
  },
  {
    "text": "So, chronic myelogenous leukemia,  I mentioned the prefix myelo- last  ",
    "start": "279000",
    "end": "285000"
  },
  {
    "text": "time or the time before referring to bone marrow, and this is a leukemia  ",
    "start": "285000",
    "end": "291000"
  },
  {
    "text": "of cells coming from the bone marrow from the myeloid cells in the bone  ",
    "start": "291000",
    "end": "297000"
  },
  {
    "text": "marrow, which are the precursors of things like macrophages  ",
    "start": "297000",
    "end": "303000"
  },
  {
    "text": "and granulocytes.  So, these are cells which are   playing an important role in the immune response,   ",
    "start": "303000",
    "end": "312000"
  },
  {
    "text": "and during this chronic myelogenous leukemia disease,    which is called CML,  there could be a period of three or  ",
    "start": "312000",
    "end": "321000"
  },
  {
    "text": "four years where individuals develop large numbers of these cells in   their blood stream.  And after a period of about three or  ",
    "start": "321000",
    "end": "330000"
  },
  {
    "text": "four years, all of a sudden there is an eruption into what's called blast   crisis.  And you may recall I mentioned the word blast also on one  ",
    "start": "330000",
    "end": "338000"
  },
  {
    "text": "occasion earlier.  This all fits together in a nice   puzzle.  Blast refers to primitive,  embryonic-like cells, and all of a  ",
    "start": "338000",
    "end": "346000"
  },
  {
    "text": "sudden there is an eruption of primitive, embryonic-like cells,    less differentiated like these macrophages and granulocytes,   ",
    "start": "346000",
    "end": "354000"
  },
  {
    "text": "which until this point had been present in vastly excessive numbers   in the blood.  There's blast crisis.   ",
    "start": "354000",
    "end": "363000"
  },
  {
    "text": "This leads to acute myelogenous leukemia, and death ensues usually   within a year or two,  or that's been traditionally the  ",
    "start": "363000",
    "end": "373000"
  },
  {
    "text": "case.  No one really had any idea about the possible causative   mechanisms of the disease,  and that allows me to use another  ",
    "start": "373000",
    "end": "382000"
  },
  {
    "text": "word which you might one day come across if you should stay in   biomedical research.  And that is the etiologic agents.   ",
    "start": "382000",
    "end": "392000"
  },
  {
    "text": "When we talk about etiologic agents,  we talk about the agents which are   causally responsible for inducing a disease.  These can be external  ",
    "start": "392000",
    "end": "401000"
  },
  {
    "text": "agents, or they could even be internal agents,    molecules inside cells which are responsible for the creation of the  ",
    "start": "401000",
    "end": "411000"
  },
  {
    "text": "disease.  And the key discovery was made in 1960 when individuals were   looking at the chromosomal makeup of the CML cells.   ",
    "start": "411000",
    "end": "421000"
  },
  {
    "text": "The chromosomal makeup,  I'll use another word just so we   could expand our vocabulary this morning, the chromosomal makeup is  ",
    "start": "421000",
    "end": "429000"
  },
  {
    "text": "often called the karyotype,  that is to say the constellation of   chromosomes that one can see at mitosis under the microscope.   ",
    "start": "429000",
    "end": "438000"
  },
  {
    "text": "Keep in mind, as we've said before,  that during the interphase of the   cell cycle, chromosomes are essentially invisible,   ",
    "start": "438000",
    "end": "447000"
  },
  {
    "text": "but during the metaphase of mitosis they become condensed,    and on that occasion, individuals noticed a 9-22 translocation.   ",
    "start": "447000",
    "end": "456000"
  },
  {
    "text": "So here is chromosome nine normally.  Here's chromosome 22.  And as you   may know, the numbering system with human chromosomes goes from the  ",
    "start": "456000",
    "end": "466000"
  },
  {
    "text": "largest number one all the way down to the smallest.    So, this is the smallest,  with the exception of the Y  ",
    "start": "466000",
    "end": "477000"
  },
  {
    "text": "chromosome.  And what they notice was instead of   seeing this regular chromosomal array, they noticed instead what  ",
    "start": "477000",
    "end": "484000"
  },
  {
    "text": "looked very much like a structure of this sort here, i.e.    a translocation.    ",
    "start": "484000",
    "end": "515000"
  },
  {
    "text": "And this translocation resulted in a swapping of sequences between these   two chromosomes.  Note, by the way,   ",
    "start": "515000",
    "end": "523000"
  },
  {
    "text": "this is reciprocal,  i.e. in the sense that nine donates   something to 22,  and 22 donates something to nine.   ",
    "start": "523000",
    "end": "531000"
  },
  {
    "text": "However, the segments that are swapped are not necessarily of equal   size.  So, it turns out here that in this case, chromosome nine has  ",
    "start": "531000",
    "end": "539000"
  },
  {
    "text": "actually gained a lot more than chromosome 22 gained as a   consequence of this exchange of genetic segments.   ",
    "start": "539000",
    "end": "548000"
  },
  {
    "text": "And this 9-22 translocation made the smallest chromosome even smaller.    So, this was already the smallest chromosome as I mentioned besides  ",
    "start": "548000",
    "end": "556000"
  },
  {
    "text": "the smallest autosome,  the smallest non-sex chromosome.    Now it got even smaller because it lost some of its bulk as a  ",
    "start": "556000",
    "end": "564000"
  },
  {
    "text": "consequence of this chromosomal translocation.    And because this discovery was made in Philadelphia,   ",
    "start": "564000",
    "end": "573000"
  },
  {
    "text": "it became known as the Philadelphia chromosome.  This is now about 40   years ago, or as it's sometimes called, PH-1 for reasons,   ",
    "start": "573000",
    "end": "582000"
  },
  {
    "text": "I don't know why it's called PH-1 except for Philadelphia.    And, as investigators began to look at other cases of chronic  ",
    "start": "582000",
    "end": "591000"
  },
  {
    "text": "myelogenous leukemia,  they discovered that this   translocation was present at the Philadelphia chromosome most  ",
    "start": "591000",
    "end": "600000"
  },
  {
    "text": "importantly was identifiable in virtually all cases,    more than 95% of the cases of chronic myelogenous leukemia.   ",
    "start": "600000",
    "end": "609000"
  },
  {
    "text": "And moreover, this chromosome was present as well in the more   differentiated macrophages and granulocytes that were present and  ",
    "start": "609000",
    "end": "618000"
  },
  {
    "text": "circulating in the blood of the CML patients.  And that began to suggest   the notion that there was a stem cell of some sort,   ",
    "start": "618000",
    "end": "627000"
  },
  {
    "text": "oligopotential stem cell that created various kinds of more   differentiated white blood cells that had sustained this chromosomal  ",
    "start": "627000",
    "end": "636000"
  },
  {
    "text": "translocation because that's what it is, a translocalization,    a translocation, that all the cells of these patients had sustained this  ",
    "start": "636000",
    "end": "646000"
  },
  {
    "text": "chromosomal translocation.  And that began to suggest the   notion that somehow as a consequence of a random genetic accident  ",
    "start": "646000",
    "end": "656000"
  },
  {
    "text": "happening in these people's blood,  this particular chromosome was   repeatedly identified.  And it was with great likelihood  ",
    "start": "656000",
    "end": "667000"
  },
  {
    "text": "causally or etiologically important in the genesis of the disease.   ",
    "start": "667000",
    "end": "673000"
  },
  {
    "text": "But that in itself led nowhere.  One could simply talk about its  ",
    "start": "673000",
    "end": "680000"
  },
  {
    "text": "association until work from a totally unrelated area,   ",
    "start": "680000",
    "end": "687000"
  },
  {
    "text": "which is to say the study of retroviruses discovered Abelson  ",
    "start": "687000",
    "end": "693000"
  },
  {
    "text": "murine leukemia virus.  And Abelson was named after the  ",
    "start": "693000",
    "end": "699000"
  },
  {
    "text": "fellow, Herb Abelson,  who first discovered it at NIH and   undertook its molecular characterization here in our own  ",
    "start": "699000",
    "end": "708000"
  },
  {
    "text": "cancer center,  and Abelson discovered that this   virus which he studied carried the ends of the murine leukemia virus,   ",
    "start": "708000",
    "end": "718000"
  },
  {
    "text": "which was a parental virus.  It was as hybrid virus.    And into the middle of it,  Abelson leukemia virus has acquired  ",
    "start": "718000",
    "end": "728000"
  },
  {
    "text": "a cellular proto-oncogene,  which it had activated into an   oncogene.  And therefore,  here we have a situation where a  ",
    "start": "728000",
    "end": "738000"
  },
  {
    "text": "cellular gene like sarc in the case of Rous Sarcoma Virus has been   activated.  This became called ABL for obvious reasons.   ",
    "start": "738000",
    "end": "748000"
  },
  {
    "text": "And this gene, it turned out,  was critically important in   understanding hwo the chromosomal translocation led to cancer.   ",
    "start": "748000",
    "end": "758000"
  },
  {
    "text": "In fact, if one infected mice with a retrovirus carrying this genome,    this is just to indicate the fact that the repeat ends,   ",
    "start": "758000",
    "end": "768000"
  },
  {
    "text": "the long terminal repeat ends of this provirus,    they occur twice at the ends of this retrovirus.  If one infected a mouse  ",
    "start": "768000",
    "end": "778000"
  },
  {
    "text": "with the Abelson virus,  out came a disease which was   superficially similar at least to chronic myelogenous leukemia.   ",
    "start": "778000",
    "end": "788000"
  },
  {
    "text": "And that began a search,  then, for the chromosomal   localization of the Abel proto-oncogene.   ",
    "start": "788000",
    "end": "798000"
  },
  {
    "text": "And what was discovered subsequently, fascinatingly enough,    was that the Abel proto-oncogene was right at the break point between two  ",
    "start": "798000",
    "end": "809000"
  },
  {
    "text": "chromosomes, nine and 22.  And what happened as a consequence   of this translocation,  and the resulting fusion of this  ",
    "start": "809000",
    "end": "818000"
  },
  {
    "text": "chromosome with this chromosome was the creation of a fuse gene,    a hybrid gene that now carried the reading frames of two previously  ",
    "start": "818000",
    "end": "826000"
  },
  {
    "text": "unconnected gene,  one on chromosome nine,    and one on chromosome 22.  Here's the normal, Abel protein.   ",
    "start": "826000",
    "end": "834000"
  },
  {
    "text": "It's called C Abel, meaning the cellular or the normal form of Abel.    And you see it up here.  It's shown in a very schematic way.   ",
    "start": "834000",
    "end": "842000"
  },
  {
    "text": "And here's a second protein which is encoded on the other chromosome.    So, Abel is encoded here, and the other gene, which is called BCR is  ",
    "start": "842000",
    "end": "851000"
  },
  {
    "text": "encoded here, and as a consequence of the translocation,    Abel is encoded here.  BCR is encoded here.  As a consequence of  ",
    "start": "851000",
    "end": "859000"
  },
  {
    "text": "the translocation,  one now has not only the fusion of   chromosomal segments.  But one has the fusion of the  ",
    "start": "859000",
    "end": "868000"
  },
  {
    "text": "reading frames of two previously unlinked genes.    And here, one creates as a consequence of these fusions,   ",
    "start": "868000",
    "end": "878000"
  },
  {
    "text": "any one of a series of three quite distinct fusion proteins,    which do not naturally preexist in the normal cell.   ",
    "start": "878000",
    "end": "888000"
  },
  {
    "text": "And there shown here is P-1 85,  P-2 10, and P-2 30.  These   translocations allow different parts of a second gene called BCR.   ",
    "start": "888000",
    "end": "898000"
  },
  {
    "text": "BCR refers to breakpoint cluster region.  The area of the point of   fusion is called the breakpoint between the two genes.   ",
    "start": "898000",
    "end": "906000"
  },
  {
    "text": "So, the point where each gene is cut and fused with the other is   called the breakpoint.  And it turns out that within the  ",
    "start": "906000",
    "end": "914000"
  },
  {
    "text": "region of the chromosome where BCR maps, there's actually three sites   at which the fusion can occur.  If you look carefully at this  ",
    "start": "914000",
    "end": "922000"
  },
  {
    "text": "diagram, you see that there's differing extents of the BCR protein,    which can be contributed to the fusion protein.   ",
    "start": "922000",
    "end": "930000"
  },
  {
    "text": "And, what this says,  in effect, is the following,    that here, let's just refer to this diagram right up here.   ",
    "start": "930000",
    "end": "940000"
  },
  {
    "text": "Notice, by the way, in all three of these, that the Abel protein is  ",
    "start": "940000",
    "end": "946000"
  },
  {
    "text": "present at the C terminal end of the protein.  The BCR is present at the   end terminal end.  So, here's the BCR gene.   ",
    "start": "946000",
    "end": "957000"
  },
  {
    "text": "Here's the Abel gene down here.  And what investigators found is that   there could be a break at this part of the BCR gene,   ",
    "start": "957000",
    "end": "965000"
  },
  {
    "text": "at this part of the BCR gene,  or at this part of the BCR gene,    resulting always in the fusion of Abel, to one, or two,   ",
    "start": "965000",
    "end": "973000"
  },
  {
    "text": "or three different kinds of BCR proteins.  And,    breakpoint cluster region signified the fact that there was a whole  ",
    "start": "973000",
    "end": "981000"
  },
  {
    "text": "cluster of sites in the previously existing BCR gene to which this   fusion could take place,  resulting, if the break occurred  ",
    "start": "981000",
    "end": "989000"
  },
  {
    "text": "here, the breakpoint occurred here,  and BCR to get the longer one.    Here you get the medium-sized one; here you'd get the shortest one.   ",
    "start": "989000",
    "end": "997000"
  },
  {
    "text": "And, interestingly enough, as one explored virtually,    other kinds of different leukemias,  one could see different of these  ",
    "start": "997000",
    "end": "1005000"
  },
  {
    "text": "fusion proteins that were produced.  Here's chronic, myelogenous   leukemia, which I talked to you about before.  Here is acute  ",
    "start": "1005000",
    "end": "1013000"
  },
  {
    "text": "lymphocytic leukemia,  and here's chronic and neutrophylic   leukemia, three different kinds of leukemia.  We don't have to worry  ",
    "start": "1013000",
    "end": "1021000"
  },
  {
    "text": "about the details of these diseases,  aside from the fact to say that the   structure of this fusion protein encourages the outgrowth of  ",
    "start": "1021000",
    "end": "1029000"
  },
  {
    "text": "different kinds of stem cells in the bone marrow, which in turn create   three different kinds of diseases.  Most importantly for our discussion  ",
    "start": "1029000",
    "end": "1037000"
  },
  {
    "text": "was an attempt to understand the nature of the resulting fusion   protein, which as a consequence of this fusion caused by the  ",
    "start": "1037000",
    "end": "1045000"
  },
  {
    "text": "chromosomal translocation now clearly acquired biological powers   that did not preexist in either of the two parental proteins.   ",
    "start": "1045000",
    "end": "1053000"
  },
  {
    "text": "These various notations here indicate a whole series of different   functions which are associated with the Abel protein,   ",
    "start": "1053000",
    "end": "1061000"
  },
  {
    "text": "and alternatively with the BCR protein.  And we don't need to get   into them, except to say that each one of these different names here  ",
    "start": "1061000",
    "end": "1069000"
  },
  {
    "text": "allows the protein on its own to associate with other proteins and do   activated downstream signaling cascade.   ",
    "start": "1069000",
    "end": "1078000"
  },
  {
    "text": "What's most important about our discussion is the realization that   this SH-1 domain,  indicated here, SH-1 refers to the  ",
    "start": "1078000",
    "end": "1089000"
  },
  {
    "text": "sarcomology domain,  equals sarcomology, equals a  ",
    "start": "1089000",
    "end": "1095000"
  },
  {
    "text": "tyrosine kinase.  And therefore, what one has here is  ",
    "start": "1095000",
    "end": "1101000"
  },
  {
    "text": "a protein, which is much more elaborate than sarc,   ",
    "start": "1101000",
    "end": "1107000"
  },
  {
    "text": "has vastly more signaling capabilities,   ",
    "start": "1107000",
    "end": "1113000"
  },
  {
    "text": "by virtue of the fact that these different domains that are indicated   here allow the resulting fusion protein to grab hold of a whole  ",
    "start": "1113000",
    "end": "1122000"
  },
  {
    "text": "bunch of different signally partners so that it can send out a diverse   array of downstream activating signals.  If one examined the  ",
    "start": "1122000",
    "end": "1132000"
  },
  {
    "text": "structure of the SH-1 domain,  it had a tyrosine kinase activity   very much like sarc,  and most importantly,   ",
    "start": "1132000",
    "end": "1142000"
  },
  {
    "text": "if one introduced this fusion protein into a retrovirus,    now instead of Abel, one could make a BCR Abel fusion protein.   ",
    "start": "1142000",
    "end": "1152000"
  },
  {
    "text": "One could put this into a retrovirus as before, just like up here.    One could infect mice with it,  and now get out of a disease which  ",
    "start": "1152000",
    "end": "1161000"
  },
  {
    "text": "was indistinguishable,  in essence, from chronic myelogenous   leukemia in humans.  If one put a subtle point mutation  ",
    "start": "1161000",
    "end": "1170000"
  },
  {
    "text": "in the tyrosine kinase domain,  all of the able protein, here is the   tyrosine kinase domain,  SH-1, up here.  Here, we see the  ",
    "start": "1170000",
    "end": "1178000"
  },
  {
    "text": "tyrosine kinase domains represented in the three different fusion   proteins.  Keep in mind SH-1 is always the tyrosine kinase domain.   ",
    "start": "1178000",
    "end": "1187000"
  },
  {
    "text": "If one put a subtle, inactivating point mutation in the tyrosine   kinase domain,  that immediately wiped out all  ",
    "start": "1187000",
    "end": "1196000"
  },
  {
    "text": "biological powers of creating leukemias on the part of this   retrovirus here,  or any one of the other closely  ",
    "start": "1196000",
    "end": "1204000"
  },
  {
    "text": "related kinds of fusion proteins.  And therefore,    that indicated that the tyrosine kinase domain indicated right here  ",
    "start": "1204000",
    "end": "1213000"
  },
  {
    "text": "was really critical to creating the tumor, and that any effects on its   tyrosine kinase signaling ability would, in the end,   ",
    "start": "1213000",
    "end": "1221000"
  },
  {
    "text": "result in the collapse of the tumor,  or the inability of the resulting   retrovirus to actually create cancer.   ",
    "start": "1221000",
    "end": "1230000"
  },
  {
    "text": "And so, now one had,  really for the first time,    a clear demonstration of how a commonly occurring human cancer,   ",
    "start": "1230000",
    "end": "1238000"
  },
  {
    "text": "chronic myelogenous leukemia, is unfortunately not so rare,    could arise as a consequence of some random, chromosomal translocation  ",
    "start": "1238000",
    "end": "1246000"
  },
  {
    "text": "event.  You might ask,  why does one always get this   particular kind of translocation?  Well, the answer is, we don't  ",
    "start": "1246000",
    "end": "1254000"
  },
  {
    "text": "really know.  It would almost seem as if there's a homing device which   causes this fragment and this fragment to target each other and to  ",
    "start": "1254000",
    "end": "1262000"
  },
  {
    "text": "exchange one another.  It's probably not the case.    What probably happens is that chromosomal translocations take  ",
    "start": "1262000",
    "end": "1271000"
  },
  {
    "text": "place rather randomly within the bone marrow, and on rare occasion   there is a chromosomal translocation that creates exactly this kind of  ",
    "start": "1271000",
    "end": "1279000"
  },
  {
    "text": "fusion.  And this kind of fusion,  in turn, is what's responsible for   creating this fusion protein,  and this fusion protein in turn  ",
    "start": "1279000",
    "end": "1287000"
  },
  {
    "text": "creates the outgrowth of this CML,  the chronic myelogenous leukemia   disease.  So what that means is really that a  ",
    "start": "1287000",
    "end": "1296000"
  },
  {
    "text": "randomly occurring chromosomal translocation on rare occasion hits   a genetic jackpot,  and the cell which happens to have  ",
    "start": "1296000",
    "end": "1304000"
  },
  {
    "text": "acquired this kind of chromosomal translocation now begins to   proliferate wildly,  creating first chronic myelogenous  ",
    "start": "1304000",
    "end": "1312000"
  },
  {
    "text": "leukemia, and then subsequently erupting into a subsequent acute   phase where there are seemingly additional genetic alterations  ",
    "start": "1312000",
    "end": "1320000"
  },
  {
    "text": "beyond this chromosomal translocation that conspire with the   initially present chromosomal translocation to create a very  ",
    "start": "1320000",
    "end": "1328000"
  },
  {
    "text": "aggressive disease which rapidly leads to the death of the   leukemia patient.  That offered, in principle,   ",
    "start": "1328000",
    "end": "1336000"
  },
  {
    "text": "an attractive way of beginning to develop an anti-cancer therapeutic   because what one might imagine was that one could develop a tyrosine  ",
    "start": "1336000",
    "end": "1346000"
  },
  {
    "text": "kinase inhibitor.    ",
    "start": "1346000",
    "end": "1358000"
  },
  {
    "text": "Now keep in mind that tyrosine kinases are a class of enzymes which   attach phosphate groups onto the tyrosine residues of various  ",
    "start": "1358000",
    "end": "1366000"
  },
  {
    "text": "substrate proteins.  And keep in mind as well the fact   that we drew a series of growth factor receptors which have tyrosine  ",
    "start": "1366000",
    "end": "1375000"
  },
  {
    "text": "kinase domains in them.  And I'm drawing the tyrosine kinase   domains here like this,  that when these growth factor  ",
    "start": "1375000",
    "end": "1386000"
  },
  {
    "text": "receptors become activated,  they attach phosphate groups onto   the tails of one another.  And I'll draw those phosphate  ",
    "start": "1386000",
    "end": "1397000"
  },
  {
    "text": "groups like this,  i.e. the binding of ligand or let's   say epidermal growth factor ligand or plate ligand causes the two  ",
    "start": "1397000",
    "end": "1408000"
  },
  {
    "text": "receptors, which are normally mobilized in the plasma membrane to   come together to transphosphorylate one another,   ",
    "start": "1408000",
    "end": "1419000"
  },
  {
    "text": "and having done so,  to acquire actively signaling powers,    because once these phosphates become attached, they now represent sites  ",
    "start": "1419000",
    "end": "1429000"
  },
  {
    "text": "where other molecules can anchor themselves and send out downstream   signals.  In fact,  there are altogether 90 different  ",
    "start": "1429000",
    "end": "1439000"
  },
  {
    "text": "tyrosine kinases encoded in the human genome.   ",
    "start": "1439000",
    "end": "1445000"
  },
  {
    "text": "And so, to the extent that these tyrosine kinases become   hyperactivated in various kinds of human cancers,   ",
    "start": "1445000",
    "end": "1453000"
  },
  {
    "text": "this represents in principle a very attractive way of developing an   anti-cancer therapeutic.  But let's think about the problems  ",
    "start": "1453000",
    "end": "1461000"
  },
  {
    "text": "that are inherent in such a compound.  First of all,    if one wants to develop an anti-cancer therapeutic,   ",
    "start": "1461000",
    "end": "1469000"
  },
  {
    "text": "it must be reasonably specific for the Abelson tyrosine kinase,    and not the 89 kinds of tyrosine kinases that also coexist in the  ",
    "start": "1469000",
    "end": "1478000"
  },
  {
    "text": "human genome, and are active,  and apparently responsible for   normal cell metabolism in a whole variety of normal cell types.   ",
    "start": "1478000",
    "end": "1488000"
  },
  {
    "text": "So, one has to begin to think about the issue of cell activity.    How can one possibly make a low molecular weight compound,   ",
    "start": "1488000",
    "end": "1498000"
  },
  {
    "text": "which is selectively able to inactivate the Abelson tyrosine   kinase as indicated here,  the SH-1 group,   ",
    "start": "1498000",
    "end": "1508000"
  },
  {
    "text": "but doesn't disturb a whole variety of other tyrosine kinases that are   responsible for other normal physiological mechanisms.   ",
    "start": "1508000",
    "end": "1515000"
  },
  {
    "text": "Well, you'll say that's pretty easy.  We have 90 different genes.    Each of the 90 different genes makes a distinct protein,   ",
    "start": "1515000",
    "end": "1523000"
  },
  {
    "text": "and these proteins should be very different.  And therefore,    if one can, in fact, if one does the three-dimensional structure of these  ",
    "start": "1523000",
    "end": "1531000"
  },
  {
    "text": "proteins, all the tyrosine kinases look quite similar.    They have a biload structure.  Here is the active site of the  ",
    "start": "1531000",
    "end": "1540000"
  },
  {
    "text": "enzyme.  That is to say,  in here is the catalytic cleft,   ",
    "start": "1540000",
    "end": "1546000"
  },
  {
    "text": "the site where the actual catalysis takes place, the site where the   gamma phosphate of ATP is taken from the ATP and attached to a substrate  ",
    "start": "1546000",
    "end": "1557000"
  },
  {
    "text": "protein to the hydroxyl of a tyrosine of a protein that's about  ",
    "start": "1557000",
    "end": "1563000"
  },
  {
    "text": "to be phosphorylated.  So, you just make a low moleculoid   chemical that's specific for the tyrosine kinase domain of the Abel  ",
    "start": "1563000",
    "end": "1571000"
  },
  {
    "text": "protein.  And when I draw this biload structure,    this biload structure is carried here within the SH-1 domain right  ",
    "start": "1571000",
    "end": "1578000"
  },
  {
    "text": "here.  So, this has a biload structure.  It's obviously not   indicated here in this very schematic drawing.   ",
    "start": "1578000",
    "end": "1586000"
  },
  {
    "text": "The problem with that is the following.    All of the SH-1 domains,  all of the tyrosine kinase domains  ",
    "start": "1586000",
    "end": "1593000"
  },
  {
    "text": "are evolutionarily closely related to one another.    They're all derived from the precursors of the tyrosine kinase  ",
    "start": "1593000",
    "end": "1601000"
  },
  {
    "text": "domain that probably existed maybe 600 or 700 million years ago,    and has as a consequence of gene duplication been diversified to make  ",
    "start": "1601000",
    "end": "1609000"
  },
  {
    "text": "90 different tyrosine kinases.  And if you look under x-ray   crystallography at the three dimensional structure of all these  ",
    "start": "1609000",
    "end": "1617000"
  },
  {
    "text": "tyrosine kinases,  they all pretty much look like this,    i.e. they all have rather similar catalytic clefts because they  ",
    "start": "1617000",
    "end": "1624000"
  },
  {
    "text": "diverge from a common ancestral protein, and they retain this three   dimensional configuration because this three dimensional configuration  ",
    "start": "1624000",
    "end": "1632000"
  },
  {
    "text": "seems to be important for the retention of their function.    You could imagine, conversely,  that if there were some descendants  ",
    "start": "1632000",
    "end": "1639000"
  },
  {
    "text": "of the ancestral tyrosine kinase domain that some of them became   mutant and lost its three dimensional structure.   ",
    "start": "1639000",
    "end": "1646000"
  },
  {
    "text": "Those descendant kinases would lose their ability to phosphorylate   tyrosines on substrate proteins,  and therefore would be eliminated  ",
    "start": "1646000",
    "end": "1654000"
  },
  {
    "text": "from the gene pool because they would be defective.    And that explains the strong conservatism in the structure of  ",
    "start": "1654000",
    "end": "1662000"
  },
  {
    "text": "these 90 different enzymes.  They all look very similar to one   another, and that creates a great difficulty for the drug developer  ",
    "start": "1662000",
    "end": "1670000"
  },
  {
    "text": "because a low molecular weight drug,  which one would like to develop,    that fits in here.  So, here I'll draw a low molecular  ",
    "start": "1670000",
    "end": "1678000"
  },
  {
    "text": "weight drug that interacts in a stereo-specific fashion with the   amino acid residues that are aligning this pocket,   ",
    "start": "1678000",
    "end": "1686000"
  },
  {
    "text": "this catalytic cleft, might bind and nicely inactivate the tyrosine   kinase domain of Abel.  But at the same time,   ",
    "start": "1686000",
    "end": "1695000"
  },
  {
    "text": "it might also bind and inactivate a whole series of other tyrosine   kinases, and that in turn could lead to therapeutic disaster.   ",
    "start": "1695000",
    "end": "1703000"
  },
  {
    "text": "For instance, if you had a non-selective agent,    you could treat a chronic myelogenous leukemia patient with a  ",
    "start": "1703000",
    "end": "1711000"
  },
  {
    "text": "low molecular weight inhibitor,  a low molecular weight compound,    which would get into this pocket of the BCR Abel protein.   ",
    "start": "1711000",
    "end": "1719000"
  },
  {
    "text": "But it might similarly get into the catalytic cleft of the EGF receptor.    And if it shot down the EGF receptor, it might cause a fatal  ",
    "start": "1719000",
    "end": "1727000"
  },
  {
    "text": "diarrhea because after all,  the EGF receptor, I will tell you,    is needed to maintain the structure of the epithelial lining of the  ",
    "start": "1727000",
    "end": "1736000"
  },
  {
    "text": "colon.  And so,  you might kill the patient simply   because you had deprived the cells in that person's colon of their  ",
    "start": "1736000",
    "end": "1744000"
  },
  {
    "text": "ability to maintain themselves.  There are a whole series of growth   factor receptors that are required for hematapoeisis that we discussed  ",
    "start": "1744000",
    "end": "1752000"
  },
  {
    "text": "last time.  And there,  once again, if you had a   nonselective compound,  which got into the domain of one of  ",
    "start": "1752000",
    "end": "1760000"
  },
  {
    "text": "the growth factor receptors that is responsible for hematapoeisis,    you might shut down the entire bone marrow, and once again kill the  ",
    "start": "1760000",
    "end": "1767000"
  },
  {
    "text": "patient.  I'm just giving you those as overly dramatic examples of the   fact that cell activity is an extremely important consideration in  ",
    "start": "1767000",
    "end": "1775000"
  },
  {
    "text": "developing such a drug.  The other thing is affinity for the   target, for the catalytic cleft that is being targeted.   ",
    "start": "1775000",
    "end": "1788000"
  },
  {
    "text": "What do I mean by affinity?  If you look at those response  ",
    "start": "1788000",
    "end": "1796000"
  },
  {
    "text": "curves of various compounds,  what you see is the following.   ",
    "start": "1796000",
    "end": "1804000"
  },
  {
    "text": "You can draw out a line that looks like this, a graph that looks like  ",
    "start": "1804000",
    "end": "1812000"
  },
  {
    "text": "this, where here we have log of drug concentration.   ",
    "start": "1812000",
    "end": "1820000"
  },
  {
    "text": "And here is 10-4,  here, let's do the other one,   ",
    "start": "1820000",
    "end": "1828000"
  },
  {
    "text": "10-8 molar, 10-7 molar, 10-6, 10-5,  10-4.   ",
    "start": "1828000",
    "end": "1836000"
  },
  {
    "text": "And this is molar drug concentration.  And here is the percentage of  ",
    "start": "1836000",
    "end": "1842000"
  },
  {
    "text": "inhibition.  Let's say,  for example, we were able to take  ",
    "start": "1842000",
    "end": "1849000"
  },
  {
    "text": "the BCR Abel protein and study it in a test tube.  And let's say we were  ",
    "start": "1849000",
    "end": "1855000"
  },
  {
    "text": "interested in studying how well its tyrosine kinase activity responded  ",
    "start": "1855000",
    "end": "1862000"
  },
  {
    "text": "to an applied drug that we developed against it.   ",
    "start": "1862000",
    "end": "1869000"
  },
  {
    "text": "So, here's the percentage of inhibition of tyrosine kinase  ",
    "start": "1869000",
    "end": "1876000"
  },
  {
    "text": "activity of BCR Abel protein.  Now, I might be able to develop a  ",
    "start": "1876000",
    "end": "1884000"
  },
  {
    "text": "drug whose dose response curve would look like this.   ",
    "start": "1884000",
    "end": "1892000"
  },
  {
    "text": "And you'll say,  well, that's terrific.    That's a drug which shuts down BCR Abel.  We haven't even dealt with  ",
    "start": "1892000",
    "end": "1900000"
  },
  {
    "text": "the issue of cell activity,  but let's look at where one begins   to see a dose response right here,  10-5 molar.  And if you calculate  ",
    "start": "1900000",
    "end": "1908000"
  },
  {
    "text": "back as to how much of the drug you need to deliver in order to shut   down the BCR Abel protein in a patient, the size of the pill they'd  ",
    "start": "1908000",
    "end": "1916000"
  },
  {
    "text": "have to get would probably be this big everyday.    So, what you need to do is you need to be an acceptable range of drug  ",
    "start": "1916000",
    "end": "1924000"
  },
  {
    "text": "concentrations is down in this area here.  And therefore,    only until you get a drug which has a dose response curve that looks  ",
    "start": "1924000",
    "end": "1932000"
  },
  {
    "text": "like this, which is two or three orders of magnitude more potent   where it's able to shut down the kinase activity already at 10-7 in a,   ",
    "start": "1932000",
    "end": "1940000"
  },
  {
    "text": "this is called a submicromolar concentration.    Micromolar is 10-6.  Here already at a tenth of a  ",
    "start": "1940000",
    "end": "1948000"
  },
  {
    "text": "micromolar, 10-7 molar,  we're already getting a shutdown of   the enzyme function.  And if one can do that,   ",
    "start": "1948000",
    "end": "1956000"
  },
  {
    "text": "then one might in principle be able to develop a pill that's this big   and give that to the patient rather than a pill that's a size of a  ",
    "start": "1956000",
    "end": "1964000"
  },
  {
    "text": "football.  And by the way,  if you have to make lots of a very   complex, organic molecule through organic synthesis that has an  ",
    "start": "1964000",
    "end": "1971000"
  },
  {
    "text": "affinity of this,  it's also very expensive.    Obviously, if you can make a compound that's a hundredfold more  ",
    "start": "1971000",
    "end": "1978000"
  },
  {
    "text": "potent and requires a hundredfold less material to deliver to the   patient body, then you might have some success in treating  ",
    "start": "1978000",
    "end": "1986000"
  },
  {
    "text": "the patient.  Here's another issue.    So, we've talked about cell activity.  We've talked about  ",
    "start": "1986000",
    "end": "1993000"
  },
  {
    "text": "potency or affinity,  affinity for the substrate or   potency.  So, this would be an acceptable drug.   ",
    "start": "1993000",
    "end": "2000000"
  },
  {
    "text": "It works already at molar concentration where the inflection   point of this curve is.  This is an unacceptable drug at  ",
    "start": "2000000",
    "end": "2008000"
  },
  {
    "text": "10-5.  We can also talk about   pharmacokinetics.  I want to give you a feeling for  ",
    "start": "2008000",
    "end": "2016000"
  },
  {
    "text": "how complex drug development is,  and why it so rarely succeeds.  By   the way, you know how much it costs to develop a drug that's useful in  ",
    "start": "2016000",
    "end": "2024000"
  },
  {
    "text": "the clinic these days and test it on people?  Anybody have any idea?    How much?  Yeah.  It's pretty close to $1 billion,   ",
    "start": "2024000",
    "end": "2033000"
  },
  {
    "text": "between $900 million and $1 billion.  That's a lot of money.  That's more   money than you and I are going to earn together, all of us  ",
    "start": "2033000",
    "end": "2041000"
  },
  {
    "text": "maybe, in a lifetime.  OK, anyhow, pharmacokinetics,    well what's pharmacokinetics?  Glad I asked that question.   ",
    "start": "2041000",
    "end": "2050000"
  },
  {
    "text": "How long does the drug stay inside of you after you take it if you're a   cancer patient?  What happens if the drug is  ",
    "start": "2050000",
    "end": "2058000"
  },
  {
    "text": "excreted by the kidneys within minutes of its being taken,    let's say, either by injection or orally?   ",
    "start": "2058000",
    "end": "2066000"
  },
  {
    "text": "So here we can imagine,  let's talk about drug concentration.   ",
    "start": "2066000",
    "end": "2072000"
  },
  {
    "text": "I'll use the word drug concentration in blood.   ",
    "start": "2072000",
    "end": "2078000"
  },
  {
    "text": "And here's time.  And here's what some drugs look like when you give  ",
    "start": "2078000",
    "end": "2084000"
  },
  {
    "text": "them, let's say,  orally.  Here's what they look like.   ",
    "start": "2084000",
    "end": "2090000"
  },
  {
    "text": "So, let's say here's the effective drug concentration: effective  ",
    "start": "2090000",
    "end": "2096000"
  },
  {
    "text": "concentration.  And we know the effective  ",
    "start": "2096000",
    "end": "2102000"
  },
  {
    "text": "concentration from doing measurements like this.    We just measure it, work that out.  So, let's say we develop a drug  ",
    "start": "2102000",
    "end": "2110000"
  },
  {
    "text": "which is able to hit the BCR Abel protein.  What are the kinetics with   which the drug becomes soluble in the blood stream?   ",
    "start": "2110000",
    "end": "2118000"
  },
  {
    "text": "And it might look like this,  where I'm drawing here now, this is   one hour.  This is two hours.  This is three hours, four hours.   ",
    "start": "2118000",
    "end": "2126000"
  },
  {
    "text": " Is that long enough?    Well, the fact of the matter is,  if you're going to try to kill a  ",
    "start": "2126000",
    "end": "2134000"
  },
  {
    "text": "cancer cell, and that's what the name of this game is,    you want to have it around for a while because it turns out,   ",
    "start": "2134000",
    "end": "2141000"
  },
  {
    "text": "as one learned, the continued viability of the CML cancer cells of   the leukemia cells was dependent on the continued firing by the BCR Abel  ",
    "start": "2141000",
    "end": "2149000"
  },
  {
    "text": "kinase protein.  In fact, as one learned,    if one shut off firing by the tyrosine kinase molecule in a  ",
    "start": "2149000",
    "end": "2156000"
  },
  {
    "text": "chronic myelogenous leukemia cell,  the cells would implode.    They would undergo apitosis.  So, this began to reveal that in  ",
    "start": "2156000",
    "end": "2164000"
  },
  {
    "text": "fact the BCR Abel protein is not only responsible for forcing these   cells to proliferate,  but it also independently provides  ",
    "start": "2164000",
    "end": "2172000"
  },
  {
    "text": "them with anti-apoptotic signal.  It keeps them from falling over the   cliff into apitosis.  It keeps them from killing  ",
    "start": "2172000",
    "end": "2180000"
  },
  {
    "text": "themselves, and that's obviously critical for the ability of this   tumor to proliferate,  for the number of cells to expand in  ",
    "start": "2180000",
    "end": "2188000"
  },
  {
    "text": "the body of a patient.  It turns out that if you provide   these cancer cells with an effective way of shutting down their BCR Abel  ",
    "start": "2188000",
    "end": "2197000"
  },
  {
    "text": "protein for 30 or 40 or 50 minutes,  not much happens to them.  You need   to deprive them of the drug for a very long period of time,   ",
    "start": "2197000",
    "end": "2207000"
  },
  {
    "text": "well, 15-20 hours, and therefore you need pharmacokinetics that look like   this.  It needs to be present for an extended period of time,   ",
    "start": "2207000",
    "end": "2217000"
  },
  {
    "text": "or even better, let me re-draw that,  even better look like this.   ",
    "start": "2217000",
    "end": "2223000"
  },
  {
    "text": "It stays in the blood for an extended period of time.    Some drugs stay in the circulation for a long time.   ",
    "start": "2223000",
    "end": "2230000"
  },
  {
    "text": "Other drugs stay in the circulation for a very short period of time.    There's another problem which we haven't even begun to talk about,   ",
    "start": "2230000",
    "end": "2237000"
  },
  {
    "text": "and that is the metabolism of the drug.  It turns out that many drugs   that you give a patient are rapidly converted by the enzymes and the  ",
    "start": "2237000",
    "end": "2244000"
  },
  {
    "text": "liver which are normally responsible for detoxifying chemicals that come   into our body.  And therefore,   ",
    "start": "2244000",
    "end": "2252000"
  },
  {
    "text": "many of the drugs that come into our bodies are with greater or lesser   speed altered into something else,  detoxified, and therefore rendered  ",
    "start": "2252000",
    "end": "2260000"
  },
  {
    "text": "innocuous.  Now you'll say,  well, you can figure that out too,    but here's an additional fly in the ointment.  Because we are a  ",
    "start": "2260000",
    "end": "2268000"
  },
  {
    "text": "polymorphic population,  because we humans are genetically   heterogeneous,  one from the other,   ",
    "start": "2268000",
    "end": "2276000"
  },
  {
    "text": "some of us metabolize a given drug much more rapidly than others do.    And here, we have a situation where potentially, most of us might  ",
    "start": "2276000",
    "end": "2284000"
  },
  {
    "text": "metabolize a drug very quickly,  in which case the physicians would   want to give us a very high dose of the drug so that we have enough of  ",
    "start": "2284000",
    "end": "2293000"
  },
  {
    "text": "the drug around for a long enough period of time to do some effect.    So let's say that 97% of us are able to metabolize the drug very  ",
    "start": "2293000",
    "end": "2302000"
  },
  {
    "text": "quickly, and as a consequence,  we're given a very high dosage in   order to have some effective dosage reaching the tumor to compensate for  ",
    "start": "2302000",
    "end": "2311000"
  },
  {
    "text": "the fact that much of this drug is rapidly eliminated by metabolism   in the liver.  It's inter-converted into another  ",
    "start": "2311000",
    "end": "2320000"
  },
  {
    "text": "chemically innocuous compound.  Well, you'll say, that's good.    We'll just take a large dose of that compound,   ",
    "start": "2320000",
    "end": "2328000"
  },
  {
    "text": "but let's think about the other 3% in the population who metabolize   this compound very slowly.  Like the other 97%, these  ",
    "start": "2328000",
    "end": "2336000"
  },
  {
    "text": "individuals will be given a high dose of the drug because experience   shows that in general,  most human beings metabolize a drug  ",
    "start": "2336000",
    "end": "2344000"
  },
  {
    "text": "very quickly.  These individuals metabolize the   drug very slowly,  and what's going to happen to them?   ",
    "start": "2344000",
    "end": "2353000"
  },
  {
    "text": "Well, they might croak.  Why?  Because that drug is going to be   around in potent biologically active form for an extended period of time  ",
    "start": "2353000",
    "end": "2363000"
  },
  {
    "text": "in their bodies,  and might have in them a lethal   outcome.  So therefore,  we have to deal with the effects of  ",
    "start": "2363000",
    "end": "2372000"
  },
  {
    "text": "variability in drug metabolism,  variability in metabolism because it   turns out that different people metabolize the drug differently and  ",
    "start": "2372000",
    "end": "2383000"
  },
  {
    "text": "that variability in drug metabolism is vastly greater if you compare the  ",
    "start": "2383000",
    "end": "2389000"
  },
  {
    "text": "way we metabolize drugs to the way that laboratory mice metabolize   drugs.  Well, you'll say,  why should we care about how  ",
    "start": "2389000",
    "end": "2400000"
  },
  {
    "text": "laboratory mice metabolize this or that drug?   ",
    "start": "2400000",
    "end": "2406000"
  },
  {
    "text": "Why is it important?  The fact is, the first tryouts of a   candidate drug are tried out in laboratory mice where laboratory  ",
    "start": "2406000",
    "end": "2415000"
  },
  {
    "text": "mice are given a tumor,  and they're injected with the drug   to see whether the tumor begins to shrink.  But if it's the case,   ",
    "start": "2415000",
    "end": "2425000"
  },
  {
    "text": "if the laboratory mice metabolize a drug in a vastly different way than   do humans, then the outcome of working with laboratory mice might  ",
    "start": "2425000",
    "end": "2434000"
  },
  {
    "text": "be enormously misleading.  And these are just some of the   problems that bedevil the development of a drug.   ",
    "start": "2434000",
    "end": "2444000"
  },
  {
    "text": "In any case, around 1994,  at a company which was a precursor  ",
    "start": "2444000",
    "end": "2450000"
  },
  {
    "text": "of Novartis, it was called Ciba-Geigy in Basel,    Switzerland.  They developed a highly specific and potent anti-Abel,   ",
    "start": "2450000",
    "end": "2460000"
  },
  {
    "text": "low molecular weight compound,  which came to be called Leveck.   ",
    "start": "2460000",
    "end": "2466000"
  },
  {
    "text": "Or in Europe it's called Gleveck.  It's also pronounced Leveck, but   it's spelled differently.  In fact, it was one of the other  ",
    "start": "2466000",
    "end": "2475000"
  },
  {
    "text": "difficulties of developing this drug was the following.    The higher ups in the drug company who were paying for this research  ",
    "start": "2475000",
    "end": "2484000"
  },
  {
    "text": "wanted on repeated occasion to scrub this entire drug development   program.  Why?  Because the number of cases of  ",
    "start": "2484000",
    "end": "2493000"
  },
  {
    "text": "chronic myelogenous leukemia overall worldwide is relatively small.    How many are in this country every year?  I don't know,   ",
    "start": "2493000",
    "end": "2502000"
  },
  {
    "text": "10 or 15,000.  So, the question was,  economically speaking, would the   relatively small number of cases of this disease justify their investing  ",
    "start": "2502000",
    "end": "2511000"
  },
  {
    "text": "$1 billion in the development of the drug.  Maybe it would take them a   generation to get any payback from their initial investment.   ",
    "start": "2511000",
    "end": "2521000"
  },
  {
    "text": "And so, they tried time after time,  time and again, to shut down this   development program because it didn't seem to have any clear,   ",
    "start": "2521000",
    "end": "2529000"
  },
  {
    "text": "long-term economic benefit.  Of course, now we're not talking about   biology.  We're talking about economics, and rational economics.   ",
    "start": "2529000",
    "end": "2538000"
  },
  {
    "text": "This is not avarice on their part.  A drug company like that cannot go   on spending $1 billion here and $1 billion there without at one point  ",
    "start": "2538000",
    "end": "2547000"
  },
  {
    "text": "or another leading to a major financial hemorrhage.    So, Gleveck turned out to be highly specific for the Abel kinase,   ",
    "start": "2547000",
    "end": "2558000"
  },
  {
    "text": "and as it turned out, for two other kinds of kinases as well.   ",
    "start": "2558000",
    "end": "2564000"
  },
  {
    "text": "Another kind of kinase is against a tyrosine kinase receptor called KIT,   ",
    "start": "2564000",
    "end": "2570000"
  },
  {
    "text": "this is a receptor tyrosine kinase,  and another receptor tyrosine kinase  ",
    "start": "2570000",
    "end": "2576000"
  },
  {
    "text": "called the PDGF receptor,  which we've also encountered in  ",
    "start": "2576000",
    "end": "2582000"
  },
  {
    "text": "passing earlier.  These two other growth factor   receptors, KIT and the PDGF receptor also have tyrosine kinase domains.   ",
    "start": "2582000",
    "end": "2592000"
  },
  {
    "text": "They therefore follow this overall structural plan here,    and it turns out by evolutionary quirk that the structures of their  ",
    "start": "2592000",
    "end": "2601000"
  },
  {
    "text": "tyrosine kinase domains are actually similar in certain ways to the   tyrosine kinase domain of Abel,  and therefore of BCR Abel.   ",
    "start": "2601000",
    "end": "2611000"
  },
  {
    "text": "So, in fact, they didn't actually have a totally specific drug which   would attack only one out of the 90-tyrosine kinases encoded in their  ",
    "start": "2611000",
    "end": "2619000"
  },
  {
    "text": "genome.  It attacked three of the 90-tyrosine kinases,    the Abel, the KITT, and the PDGF receptor.  And this might,   ",
    "start": "2619000",
    "end": "2628000"
  },
  {
    "text": "on its own, have already proven to be the death nail for the protein,    except they began to try it out for patients, and they saw some  ",
    "start": "2628000",
    "end": "2637000"
  },
  {
    "text": "remarkable responses.  It turned out that the great   majority of CML patients who were treated with Gleveck at therapeutic  ",
    "start": "2637000",
    "end": "2648000"
  },
  {
    "text": "concentrations ended up having a rapid remission of their chronic   myelogenous leukemia disease,  which ultimately resulted in their  ",
    "start": "2648000",
    "end": "2658000"
  },
  {
    "text": "being outwardly free of the disease.  This is your question of the day.   ",
    "start": "2658000",
    "end": "2664000"
  },
  {
    "text": "So, Gleveck goes into the catalytic cleft of the Abel tyrosine kinase.    It blocks the ATP binding site because keep in mind that these  ",
    "start": "2685000",
    "end": "2694000"
  },
  {
    "text": "enzymes need to grab the gamma phosphate off of ATP and transfer it   to a protein substrate,  and it does so because it hydrogen  ",
    "start": "2694000",
    "end": "2704000"
  },
  {
    "text": "bonds to the amino acids which are lining this catalytic cleft.    In other words,  this catalytic cleft up here is  ",
    "start": "2704000",
    "end": "2712000"
  },
  {
    "text": "obviously made of amino acids,  and there are hydrogen bonds which   Gleveck can form with the amino acid resides that you're lining on both  ",
    "start": "2712000",
    "end": "2720000"
  },
  {
    "text": "sides of the cleft.  I should have brought you a picture   of that.  And,  a similar kind of hydrogen bonding  ",
    "start": "2720000",
    "end": "2727000"
  },
  {
    "text": "can occur with the amino acids that are aligning the catalytic clefts of   the PDGF receptor and KIT,  and that hydrogen bonding can occur  ",
    "start": "2727000",
    "end": "2735000"
  },
  {
    "text": "already at concentrations that are submicromolar,    less than 10-6 molar,  10-7, even sometimes 10-8 molar  ",
    "start": "2735000",
    "end": "2743000"
  },
  {
    "text": "under certain conditions.  So, it's a high affinity binding,    and it's relatively specific.  Only three out of the 90 different  ",
    "start": "2743000",
    "end": "2752000"
  },
  {
    "text": "kinases are bound.  We can do the following kind of   experiment.  If I were to add Gleveck to cells  ",
    "start": "2752000",
    "end": "2762000"
  },
  {
    "text": "with BCR Abel function,  this is the response that BCR Abel  ",
    "start": "2762000",
    "end": "2770000"
  },
  {
    "text": "would show.  Here is the response that the EGF receptor would show.   ",
    "start": "2770000",
    "end": "2777000"
  },
  {
    "text": "So, if I dose the patient at this concentration of drug,   ",
    "start": "2777000",
    "end": "2785000"
  },
  {
    "text": "Gleveck will shut down the BCR Abel protein.   ",
    "start": "2785000",
    "end": "2793000"
  },
  {
    "text": "But it won't shut down the EGF receptor, which requires vastly   higher concentrations of drug in order to shut down its tyrosine  ",
    "start": "2793000",
    "end": "2801000"
  },
  {
    "text": "kinase domain.  And right here,    we can see what we call selectivity.  The fact that this enzyme responds  ",
    "start": "2801000",
    "end": "2809000"
  },
  {
    "text": "at very log drug concentration,  this enzyme EGF receptor and its   tyrosine kinase,  it's a growth factor receptor once  ",
    "start": "2809000",
    "end": "2817000"
  },
  {
    "text": "again, requires a vastly higher concentration drug in order to   elicit an outcome.  So, what happened to the chronic  ",
    "start": "2817000",
    "end": "2824000"
  },
  {
    "text": "myelogenous leukemia patients.  The great majority of them between   70-80% had a miraculous collapse of their disease.   ",
    "start": "2824000",
    "end": "2832000"
  },
  {
    "text": "In most cases,  this disease could be monitored   microscopically.  One could look for the immature  ",
    "start": "2832000",
    "end": "2840000"
  },
  {
    "text": "myeloid cells in their blood and see where they were previously present   in vast numbers.  They were microscopically now  ",
    "start": "2840000",
    "end": "2848000"
  },
  {
    "text": "indetectable (sic).  However, in those patients where the   disease seemed to collapse,  one could still use the PCR test to  ",
    "start": "2848000",
    "end": "2858000"
  },
  {
    "text": "demonstrate there were residual cancer cells in their blood.   ",
    "start": "2858000",
    "end": "2864000"
  },
  {
    "text": "How could one do that?  Well,  let's imagine that here is the PCR   Abel fusion protein.  So, here's PCR, and here's Abel  ",
    "start": "2864000",
    "end": "2875000"
  },
  {
    "text": "over here.  You can make PCR primers,    one of which is specific for a PCR sequence, and the other of which is  ",
    "start": "2875000",
    "end": "2885000"
  },
  {
    "text": "specific for an Abel sequence,  and the only time that you'll get a   PCR product is if these two sequences exist on the same  ",
    "start": "2885000",
    "end": "2894000"
  },
  {
    "text": "messenger RNA molecule that's reverse transcribed into a CDNA.    You could even do this genomic DNA as well, and so one can specifically  ",
    "start": "2894000",
    "end": "2903000"
  },
  {
    "text": "detect using this PCR test the presence of cells which have this   chromosomal translocation.  If one of the PCR primers is against  ",
    "start": "2903000",
    "end": "2913000"
  },
  {
    "text": "BCR and the other is Abel,  and the distances between these two   primers is not too far away,  not more than, let's say, kilobase,   ",
    "start": "2913000",
    "end": "2922000"
  },
  {
    "text": "so you get rather efficient PCR amplification.    So, it turned out that the great majority of patients who were  ",
    "start": "2922000",
    "end": "2931000"
  },
  {
    "text": "cytologically cured,  cytology means a cytological   analysis represents what you see through in microscopes.   ",
    "start": "2931000",
    "end": "2940000"
  },
  {
    "text": "So these patients,  if you looked at a smear of their   blood, cytologically they were cured.  But if you used PCR analysis,   ",
    "start": "2940000",
    "end": "2948000"
  },
  {
    "text": "which is far more sensitive, one could detect residual cancer cells   that might be present in one out of 105 or one out of 106 cells moving  ",
    "start": "2948000",
    "end": "2957000"
  },
  {
    "text": "around in circulation,  which are almost invisible if you're   looking through a very complex mixture of cells through the light  ",
    "start": "2957000",
    "end": "2965000"
  },
  {
    "text": "microscope.  And so,  what happened was that patients   began to relapse,  and after a period of several years,   ",
    "start": "2965000",
    "end": "2974000"
  },
  {
    "text": "a number of patients began to show a restoration of their CML condition.    In fact, in one recent European study, indicates that between 10-12%  ",
    "start": "2974000",
    "end": "2983000"
  },
  {
    "text": "of the CML patients who were treated with Gleveck relapsed every year.    What do I mean by relapse?  I mean they show a resurgence of their  ",
    "start": "2983000",
    "end": "2992000"
  },
  {
    "text": "disease.  The disease comes back to life, and they once again   have the disease.  And interestingly enough,   ",
    "start": "2992000",
    "end": "3002000"
  },
  {
    "text": "if one now looks at their cancer cells, what do you see?   ",
    "start": "3002000",
    "end": "3008000"
  },
  {
    "text": "In virtually every case you see some alteration in the BCR Abel  ",
    "start": "3008000",
    "end": "3014000"
  },
  {
    "text": "protein.  In the great majority of instances, you see point mutations   that affect amino acid residues lining the cavity here,   ",
    "start": "3014000",
    "end": "3025000"
  },
  {
    "text": "lining the cavity of the Abel kinase protein.   ",
    "start": "3025000",
    "end": "3031000"
  },
  {
    "text": "Those amino acid substitutions do not compromise the tyrosine kinase   activity of this enzyme.  But they do prevent Gleveck from  ",
    "start": "3031000",
    "end": "3040000"
  },
  {
    "text": "binding, and as a consequence,  now you begin to have patients whose   tumors are no longer responsive to Gleveck.  And what's happened now is  ",
    "start": "3040000",
    "end": "3049000"
  },
  {
    "text": "one has developed a new generation of compounds which binds into this   pocket even in the presence of these amino acid substitutions to retreat  ",
    "start": "3049000",
    "end": "3058000"
  },
  {
    "text": "these patients.  See you on Wednesday.  ",
    "start": "3058000",
    "end": "3060666"
  }
]